BioLineRx (BLRX) Net Margin (2024 - 2026)
BioLineRx (BLRX) posted quarterly Net Margin of 1152.58% for Q4 2025, down 112545.0% year-over-year from N/an in Q4 2024, and down 403.74% quarter-over-quarter from 228.81% in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) Net Margin (2024 - 2026) Analysis & Trends
BioLineRx's Net Margin history runs 2 years deep, the most recent figure standing at 1152.58% for Q4 2025.
- In Q4 2025, Net Margin fell 112545.0% year-over-year to 1152.58%; the TTM figure through Dec 2025 stood at 171.69% (down 16382.0% YoY), while the FY2025 annual figure was 99.58%, down 6771.0% from the prior year.
- Net Margin for Q4 2025 stood at 1152.58%, down from 228.81% in the prior quarter.
- The five-year high for Net Margin was 2010.59% in Q1 2025, with the low at 1296.05% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 12.09% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -3.12% |
| 10 | BioLineRx | 6.47 Bn | 6.47 Bn | 235,000.00 | -1,029.25% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,029.25% |
| Mar 31, 2026 | -335.64% |
| Dec 31, 2025 | -1,444.85% |
| Sep 30, 2025 | -357.38% |
| Jun 30, 2025 | -1,296.05% |
| Mar 31, 2025 | 2,010.59% |
| Dec 31, 2024 | 3.33% |
| Sep 30, 2024 | -67.33% |
| Jun 30, 2024 | -58.46% |
| Mar 31, 2024 | -48.55% |